

Effects of a Nordic breakfast on cardiovascular risk factors.

Submission date

04/12/2009

Recruitment status

No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date

07/01/2010

Overall study status

Completed

☐ Statistical analysis plan

☒ Results

Last Edited

14/05/2014

Condition category

Nutritional, Metabolic, Endocrine

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Ulf Riserus

Contact details

Clinical Nutrition and Metabolism
Department of Public Health and Caring Sciences
Uppsala Science Park
Uppsala
Sweden
751 85

Additional identifiers

Protocol serial number

North B U-08-017

Study information

Scientific Title

Effects of a Nordic breakfast diet on risk markers for cardiovascular disease in healthy mildly hypercholesterolemic men and women.

Acronym

North B

Study objectives

The aim of this study is to investigate if intake of a healthy Nordic breakfast may affect risk markers for cardiovascular disease in healthy mildly hypercholesterolemic men and women.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study was approved by the regional ethic committee in Uppsala, on the 20th of January 2009 (ref: North B U-08-017, Dnr 2009/018)

Primary study design

Interventional

Study design

Randomised controlled parallel group intervention study

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Cardiovascular risk factors

Interventions

The test breakfast will include: Porridge made of oat bran. Low fat milk or yoghurt. A choice of jam (blueberries or lingonberries). Whole grain bread. Margarine with high content of polyunsaturated fatty acids (19%). Something to put on the bread such as low fat meat or pickled herring or mackerel in tomato. Fresh fruit will also be included.

Outcomes after intake of a Nordic breakfast diet in comparison to ordinary foods in mildly hypercholesterolemic men and women, (LDL-cholesterol levels > 3.0 mmol/l) will be measured after 12 weeks. There will be no follow up beyond the end of the 12 week intervention.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

The effect on LDL-cholesterol will be measured at baseline, 6 and 12 weeks.

Key secondary outcome(s)

The following will be measured at baseline, 6 and 12 weeks

1. HDL cholesterol
2. Total cholesterol
3. Triglycerides
4. High-Sensitivity C-Reactive Protein (HS-CRP)
5. Apolipoprotein A1 and B

6. Blood pressure
 7. Sagittal abdominal diameter (SAG)
 8. Hip
 9. Waist
 10. Glycated Haemoglobin (HbA1c)
- The following will be measured at baseline and 12 weeks
11. Glucose response
 12. Insulin sensitivity

Completion date

30/01/2010

Eligibility

Key inclusion criteria

1. Slightly overweight and hyperlipidemic but otherwise healthy as assessed by the results of the screening laboratory tests and judged by medical staff
2. Age ≥ 25 and ≤ 67 years at visit 1
3. Body Mass Index (BMI) ≥ 25 and ≤ 35 kg/m²
4. LDL cholesterol ≥ 3.0 mmol/l
5. Haemoglobin (Hb) ≥ 120 g/l for women and ≥ 130 g/l for men
6. Signed written informed and biobank consents

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Participation in a clinical study with blood sampling within 90 days prior to screening visit and throughout the study.
2. Use of cholesterol lowering medication <3 months prior screening visit.
3. Blood pressure >155/95 (will be measured at visit 1 for inclusion).
4. Consumption of products or supplements fortified with plant sterols or omega-3 or omega-6 or omega 9- fatty acids within 3 weeks prior to the visit 1 and no consumption at all throughout the study.
5. Allergic to certain foods
6. Slimming or medically prescribed diet/medication or a special diet (vegan and gluten-free).
7. Not able to eat porridge for breakfast every day during 12 weeks
8. Not able to eat herring or mackerel for breakfast 3 days/week during 12 weeks
9. Pregnant or lactating or wish to become pregnant during the period of the study.
10. Lack of suitability for participation in the study for any reason as judged by the personnel at Good Food Practice (GFP) research clinic.

Date of first enrolment

01/06/2009

Date of final enrolment

30/01/2010

Locations

Countries of recruitment

Sweden

Study participating centre

Clinical Nutrition and Metabolism

Uppsala

Sweden

751 85

Sponsor information

Organisation

University of Uppsala (Sweden)

ROR

<https://ror.org/048a87296>

Funder(s)

Funder type

Industry

Funder Name

Cerealia Foundation R&D (Sweden)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2015		Yes	No